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Clinical Chemistry and Laboratory Medicine 
Letter to the Editors 
Influence of C-reactive protein on thrombin generation assay 
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To the editors, 
A close association between inflammatory state, C-reactive protein (CRP) and thromboembolic events has been 
described at least a decade ago [1] but has resurfaced recently with the outbreak of the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2).[2] CRP is an acute phase reactant plasma protein considered as a systemic 
biomarker representative of the total burden of inflammation but also linked to the development of pro-
thrombotic states.[1, 2] Through direct interaction with Fc𝛾 receptors (Fc𝛾Rs) on smooth muscles cells or 
vascular endothelial cells, CRP promotes discharge of tissue factor (TF), production of pro-inflammatory 
cytokines and release of plasminogen activator inhibitor.[2] The CRP-Fc𝛾R interaction also inhibits the liberation 
of tissue-plasminogen activator, modifying the fibrinolytic balance and reducing intravascular fibrin clearance.[1] 
Under normal circumstances, plasma CRP concentrations stand between 0,2 and 8,0mg/L, but patients  being 
affected by diseases or conditions characterized by a strong inflammation express CRP levels up to 1000 times 
higher.[3] Persistent elevated CRP levels, observed in moderate to severe COVID-19 patients, in sepsis or in other 
chronic inflammatory diseases (e.g. inflammatory bowels disease) [4, 5], are reflected by higher risk of 
cardiovascular complications, especially venous thromboembolism and pulmonary thrombosis.[6] The 
assessment of the pro-thrombotic state of these patients with global coagulation tests like thrombin generation 
assays (TGA) may be relevant to assess the evolution of the disease or identify its severity, although their clinical 
utility remained to be confirmed. Nevertheless, CRP impacts coagulation assays, especially the activated partial 
thromboplastin time (aPTT) which has been reported to be dose-dependently prolonged in presence of CRP 
concentrations encountered in inflammatory states.[7, 8] It has also been demonstrated that phospholipids act 
as catalytic surfaces and, depending on their component, form complex with CRP leading to potential disturbance 
of TGA on the Calibrated Automated Thrombogram (CAT).[7] This study aims to assess how CRP impacts TGA on 
the ST-Genesia system. A comparison with the CAT system was performed, using the same triggering reagent, as 
differences between both platforms have been reported.[9] 
The study protocol was in accordance with the Declaration of Helsinki. Recruitment of healthy volunteers for the 
constitution of a normal pooled plasma (NPP) has been approved by the Ethical Committee of the CHU-UCL 
Namur, Yvoir, Belgium (approval number: B03920096633). Trisodium citrate tubes (3.2% i.e., 0.109M) were used 
for blood collection. Platelet-poor-plasma was obtained from the supernatant fraction after a double 
centrifugation for 15 minutes at 2500g . NPP was constituted of 50 healthy individuals  (median age= 20 years, 
from 18 to 56 years; mean BMI= 23 kg.m-2) not  carrier of a factor V Leiden or G20210A mutation. Human C-
reactive protein (Merk KGaA, Darmstadt,Germany)  was spiked in NPP at five plasma concentrations (0 
[phosphate buffer saline], 50, 100, 200, and 350 mg/L). These concentrations were confirmed by an 
immunoturbidimetric assay on the Cobas® 8000 (Roche Diagnostics, Meylan, France). The selected 
concentrations correlated with CRP levels observed in patients suffering from inflammatory diseases such as 
COVID-19 or rheumatoid arthritis.[3, 6] Thrombin generation (TG) was first assessed on the new automated 
system, the ST-Genesia (Diagnostica Stago, Asnières-sur-Seine, France). Secondly, TG was assessed on the CAT 
using the Thrombinoscope software version 5,0 (Thrombinoscope bv, Maastricht, the Netherlands). The 
triggering reagent on both platforms was the STG-ThromboScreen-TM (Diagnostica Stago) which contains 
phospholipids and TF (exact concentrations not provided by the manufacturer). Both TGA methods were 
performed in duplicate and assessed by 3 independent runs on each platform. The aPTT was measured at the 
highest CRP concentration (350 mg/L) and compared to the NPP buffer concentration (0 mg/L) in order to confirm 
that our model was able to replicate previous observations and to validate our experiments.[7] The aPTT was 
performed on a STA R Max system (Diagnostica Stago) using Dade®Actin®FS (Siemens Healthcare, Munich, 
Germany) as activator reagent, which has been previously proven to be sensitive to the presence of CRP.[7] All 
data and statistical analysis were  processed and performed using GraphPad Prism 8,0 for macOS (GraphPad 
Software, San Diego, California USA, www.graphpad.com). Mean velocity rate index (mVRI) was calculated for 
TGA performed on the ST-Genesia system as the algorithm does not determined it automatically. The ratio for 
the lag time (LT), time-to-peak (Ttpeak), endogenous thrombin potential (ETP), peak height (PH), and mVRI were 
calculated relative to the NPP buffer concentration (i.e. 0 mg/L). Descriptive statistics were used to describe the 
data. An ordinary one-way ANOVA was performed to assess the differences on TGA parameters of the 5 CRP 
concentrations tested. In case of significance, a Tukey’s multiple comparison test was performed. Difference 
between both analyzers was assessed using a paired t-test with individual variance computed for each 
comparison followed by a Holm-Sidak’s multiple comparison test. The threshold for significance was set at 0,05. 
Mean values and mean ratios ± standard deviation (SD) and coefficient of variation (CV%) were calculated for 
each TGA parameter at each plasma CRP concentrations. Results are reported in Table 1. Based on mean values, 
no statistically significant difference was observed between the five tested concentrations (ANOVA p-
value>0,05), regardless of the platform used. However, on the CAT system, a decrease of 7% of the ETP and an 
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increase of 10% of the mVRI were observed at the highest CRP concentration (350 mg/L) compared to NPP buffer 
concentration. 
Comparison between both platforms, represented in Figure 1, showed significant difference for LT and Ttpeak 
(Holm-Sidak p-value<0,05). LT was significantly higher at CRP levels of 50, 100 and 150 mg/L as well as Ttpeak at 
CRP levels of 50 and 150 mg/L when TGA was assessed on the CAT compared to the ST-Genesia System. 
Significant differences observed between LT and Ttpeak are possibly associated with the specific algorithm signal 
acquisition sequence specific ofto each platform. The ETP was not significantly different between both 
equipment (p-value>0,05).  
mg/L of CRP. This corresponds to a prolongation of 4,2 s and a ratio of 1,15 when compared to the baseline. This A 
similar increase was previously also observed by Devreese et al. [7]. 
As expected, the aPTT performed in our study was prolonged by 1,15 at CRP concentration of 350 mg/L. This 
correlates with results previously obtained in the study of Devreese et al. 
Different hypotheses may explain the absence of the impact of CRP on TGA. Firstly, it has been shown that the 
impact on aPTT was reagent-dependent, suggesting that the composition of the phospholipids content of the 
reagents influences the impact of CRP on aPTT clotting times.[7] It is therefore possible that the phospholipids 
content of the STG-ThromboScreen is not or weakly sensitive to the presence of CRP. Secondly, aPTT and TGA 
induce coagulation through different pathways. Indeed, aPTT induces coagulation through the intrinsic pathway 
whereas in TGA, the TF contained in the reagent activates the extrinsic pathway. A third hypothesis which 
completes the second one is the way TG is dependent to phospholipids. Namely, it has been shown that TG 
reaches a plateau at phospholipids concentrations above ± 3µM meaning that if the residual non-complexed 
phospholipids is above this threshold, the impact on TG would be negligible.[10] However, as no formal 
information is provided by the manufacturer regarding the final phospholipids concentration in the STG-
ThromboScreen reagent, this is only an assumption. 
Thus, the The The weak affinity of CRP for the phospholipids molecules contained in the STG-ThromboScreen, 
the difference in the triggering coagulation pathway and the weaker dependence for phospholipids of the TF-
induced TG are hypotheses that may explain the robustness of TG towards CRP. In conclusion, this study 
demonstrated that CRP levels up to 350 mg/L did not impact significantly TG performed either on a CAT or on a 
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ST-Genesia system. Thrombin generation assay is therefore an efficient test to assess the hemostatic function of 
patients with elevated CRP, like those in sepsis and suffering from chronic or acute inflammatory conditions. 
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Figure 1: Mean values of each TGA parameter; (A) ETP,  (B) mVRI, (C) Lag time, (D) Time-to-peak and (E) Peak height; at each CRP 
concentration (0 – 50 – 100 – 200 – 350 mg/L) for both equipments. Data from CAT system are shown in blue. Data from ST Genesia 
system are shown in orange. 


































































































Table 1: Mean values ± SD , mean ratios ± SD and calculated CV (%) of TGA parameters reported for each plasma CRP concentration on the CAT and the ST GENESIA system. Reference intervals described for each 
TGA parameter on both equipments are extracted from the article of Talon et al.[9] P-value of the one-way ANOVA expresses difference between CRP concentrations for each analyzer. P-value of the Holm-Sidak’s 
multiple comparison test shows the difference between equipment for each CRP concentration and each parameter. 
TGA parameters CRP (mg/L) 
 0 mg/mL 50 mg/mL 100 mg/mL 200 mg/mL 350 mg/mL  
 Mean values ±  
SD 
CV (%) 
Mean ratios ± 
SD 
Mean values ± 
SD 
CV (%) 
Mean ratios ± 
SD 
CV (%) 
Mean values ± 
SD 
CV (%) 
Mean ratios ± 
SD 
CV (%) 
Mean values ± 
SD 
CV (%) 
Mean ratios ± 
SD 
CV (%) 
Mean values ± 
SD 
CV (%) 







ETP (nM*min)  
CAT system 
 [1090-1320] 




1320,39 ± 23,83 1,80% 1,00 ± 0,00 1338,40 ± 35,25 2,63% 1,01 ± 0,03 2,67% 1355,93 ± 37,60 2,77% 1,03 ± 0,01 0,97% 1342,30 ± 46,36 3,45% 1,02 ± 0,02 1,76% 1314,69 ± 29,31 2,23% 1,00 ± 0,01 0,83% 0,623 
p-value of the 
Holm-Sidak test 




CAT system  
[65-105] 
79,83 ±  8,4 10,32% 1,00 ± 0,00 80,16 ± 8,90 11,10% 1,00 ± 0,01 1,33% 81,04 ± 9,05 11,17% 1,01 ± 0,01 0,86% 86,21 ± 8,20 9,52% 1,08 ± 0,01 0,59% 88,06 ± 9,95 11,30% 1,10 ± 0,03 2,50% 0,705 
ST GENESIA 
system* 
101,68 ± 4,93 4,85% 1,00 ± 0,00 104,19 ± 9,18 8,81% 0,98 ± 0,03 3,05% 102,79 ± 4,99 4,85% 1,00 ± 0,04 4,41% 103,95 ± 4,15 3,99% 0,99 ± 0,02 2,06% 104,03 ± 2,82 2,71% 1,01 ± 0,02 1,66% 0,821 
p-value of the 
Holm-Sidak test 
0,053 0,061 0,061 0,082 0,082  
Lag time (min)  
CAT system 
 [2,5-3,0] 




2,14 ± 0,07 3,21% 1,00 ± 0,00 2,19 ± 0,07 3,30% 1,02 ± 0,05 4,77% 2,20 ± 0,04 1,97% 1,03 ± 0,03 3,34% 2,17 ± 0,02 0,82% 1,01 ± 0,02 2,36% 2,23 ± 0,03 1,38% 1,04 ± 0,02 2,18% 0,376 
p-value of the 
Holm-Sidak test 
0,058 0,033* 0,033* 0,033* 0,055  
Time to peak 
(min) 
 
CAT system  
[5,2-6,3] 




4,51 ± 0,11 2,45% 1,00 ± 0,00 4,52 ± 0,06 1,26% 1,00 ± 0,04 3,56% 4,58 ± 0,02 0,52% 1,02 ± 0,02 1,91% 4,52 ± 0,05 1,20% 1,00 ± 0,03 2,95% 4,52 ± 0,03 0,60% 1,00 ± 0,02 2,08% 0,673 
p-value of the 
Holm-Sidak test 










240,54 ± 0,47 0,20% 1,00 ± 0,00 242,95 ± 9,04 3,72% 1,01 ± 0,04 3,53% 244,36 ± 6,60 2,70% 1,02 ± 0,03 2,53% 244,75 ± 9,02 3,68% 1,02 ± 0,04 3,51% 238,52 ± 4,07 1,71% 0,99 ± 0,01 1,51% 0,757 
p-value of the 
Holm-Sidak test 
0,985 0,985 0,985 0,985 0.949  
* Ranges are not set for the parameter mVRI for the ST-Genesia as this parameter was calculated.  
 
